A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-14.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Spondylarthritis with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · China.
Among the 17 studies in Spondylarthritis with a site in China, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 8th registered.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
Browse Spondylarthritis studies →6 of the 17 studies in Spondylarthritis with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–45
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–59
Nanfang Hospital, Southern Medical University · Sites in China
Ages 10–59
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 3
First in 2006; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 108 across 106 interventional studies indexed under Spondylarthritis.
Median enrollment 149 across the 10 interventional studies, 400 across the 7 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Spondylarthritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Spondylarthritis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06707194Nanfang Hospital, Southern Medical UniversityEffect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis | 2027-03-01 |
| NCT07724847Chinese PLA General HospitalMulticenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis | 2027-04-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Spondylarthritis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Ixekizumab during the double-blind and extended treatment periods (i.e.,) starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during the follow-up period.
Drug: Ixekizumab
Participants received placebo every four weeks (Q4W) by subcutaneous (SC) injection during the double-blind period. During the extension period, they received starting dose of 160 milligrams (mg) Ixekizumab in the beginning week followed by 80 mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection. No treatments were administered during follow-up period.
Drug: Ixekizumab · Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Percentage of Participants Achieving an ASAS40 Response
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Percentage of Participants Achieving an ASAS20 Response
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, baseline C-reactive protein (CRP) status, Tumor necrosis factor (TNF) inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.
Time frame: Baseline, Week 16
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score
SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)
BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.
Time frame: Baseline, Week 16
Number of Participants With Anterior Uveitis
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Baseline through Week 16
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of NSAID (150 mg/day diclofenac) was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). The total score range is from 0 to 100, higher the score greater the NSAID intake and 0 represents no intake at all. A negative change from baseline indicates less NSAID consumption.
Time frame: Baseline, Week 52
Percentage of Participants With Anti-Ixekizumab Antibodies
A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Week 16
Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.
Time frame: Week 16
The study was designed to be conducted in three periods: * Double-Blind Treatment Period (Week 0 to Week 16) * Extended Treatment Period (Week 16 to Week 52) * Follow-up Period (at least 4 weeks and up to 12 weeks after the date of the participant's last visit)
| Milestone | Placebo | Ixekizumab 80mg Q4W | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | Placebo - Follow-up Period | Ixekizumab 80mg Q4W - Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 73 | 74 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 73 | 74 | 0 | 0 | 0 | 0 |
| Completed | 71 | 74 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Ixekizumab 80mg Q4W | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | Placebo - Follow-up Period | Ixekizumab 80mg Q4W - Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 70 | 72 | 0 | 0 |
| Completed | 0 | 0 | 69 | 64 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 8 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 7 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo | Ixekizumab 80mg Q4W | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | Placebo - Follow-up Period | Ixekizumab 80mg Q4W - Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1 | 135 |
| Completed | 0 | 0 | 0 | 0 | 0 | 123 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 12 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Covid-19 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 |
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of Participants | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response in Biological Disease-modifying Antirheumatic Drug (bDMARD)-naïve Participants | 7.8 | 40.9 |
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40 % and absolute improvement from baseline of at least 2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of Participants | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Percentage of Participants Achieving an ASAS40 Response | 8.2 | 37.8 |
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of Participants | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Percentage of Participants Achieving an ASAS20 Response | 35.6 | 59.5 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness and 5. CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Least Square (LS) mean was determined by mixed-model repeated measures (MMRM) with treatment, baseline C-reactive protein (CRP) status, Tumor necrosis factor (TNF) inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.19 ± 0.103 | -1.33 ± 0.100 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Response | -0.90 ± 0.231 | -2.39 ± 0.226 |
The BASFI is a participant-reported assessment that establishes a participant's functional baseline and subsequent response to treatment. The BASFI is composed with 10 questions to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Participants respond to each question using an NRS scale (range 0 to 10). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | -0.49 ± 0.237 | -1.36 ± 0.230 |
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease. Scoring was performed by central readers. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) | -0.93 ± 1.550 | -8.65 ± 1.507 |
SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | 1.23 ± 0.740 | 3.85 ± 0.716 |
SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health. LS mean was determined by MMRM with factors for treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in 36-Item SF-36 Mental Component Summary (MCS) Score | -0.06 ± 1.027 | 0.45 ± 1.003 |
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| milligram per liter (mg/L) | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP) | 2.65 ± 1.349 | -10.10 ± 1.312 |
BASMI is a combined index comprising of 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI) | 0.06 ± 0.093 | -0.30 ± 0.090 |
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by MMRM with treatment, baseline CRP status, TNF inhibitors experience, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) | -1.06 ± 0.349 | -1.77 ± 0.361 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with factors for treatment, baseline CRP status, TNF inhibitors experience, and baseline value.
| units on a scale | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score | -1.31 ± 1.021 | -6.98 ± 0.986 |
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Participants | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Number of Participants With Anterior Uveitis | 0 | 0 |
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose and the number of days taking NSAID during a period of interest (PI). For the NSAID equivalence scoring system, "no NSAID intake" was set to a score value of 0, and the reference dose of NSAID (150 mg/day diclofenac) was set to a score value of 100. The Daily diclofenac-equivalent dose score was derived by converting each daily dose of NSAID to a percentage dose equivalent of 150 mg diclofenac. ASAS-NSAID score = (equivalent NSAID score) x (days of intake during PI) x (days per week)/(PI in days). The total score range is from 0 to 100, higher the score greater the NSAID intake and 0 represents no intake at all. A negative change from baseline indicates less NSAID consumption.
| Units on a scale | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period |
|---|---|---|
| Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score | -30.71 ± 46.481 | -26.13 ± 41.384 |
A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| Percentage of participants | Placebo | Ixekizumab 80mg Q4W |
|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 4.1 | 13.5 |
Pharmacokinetics (PK): Steady-state trough serum concentration of Ixekizumab at week 16.
| microgram per milliliters (µg/mL) | Ixekizumab 80mg Q4W |
|---|---|
| Pharmacokinetics (PK): Trough Ixekizumab Concentration at Steady State (Ctrough ss) | 3.89 ± 52 |
Collected over Baseline to Follow-up (Up To 64 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/73 (0%) | 1/73 (1.4%) | 17/73 (23.3%) |
| Ixekizumab 80mg Q4W | 0/74 (0%) | 2/74 (2.7%) | 31/74 (41.9%) |
| Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | 0/70 (0%) | 6/70 (8.6%) | 43/70 (61.4%) |
| Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | 0/72 (0%) | 4/72 (5.6%) | 41/72 (56.9%) |
| Placebo - Follow-up Period | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Ixekizumab 80mg Q4W - Follow-up Period | 0/135 (0%) | 1/135 (0.7%) | 11/135 (8.1%) |
| Event | Placebo | Ixekizumab 80mg Q4W | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | Placebo - Follow-up Period | Ixekizumab 80mg Q4W - Follow-up Period |
|---|---|---|---|---|---|---|
| Male genital tract tuberculosisInfections and infestations | 0/65 | 0/64 | 1/62 | 0/62 | 0/1 | 0/119 |
| Auricular haematomaInjury, poisoning and procedural complications | 0/73 | 0/74 | 1/70 | 0/72 | 0/1 | 0/135 |
| Brain contusionInjury, poisoning and procedural complications | 0/73 | 0/74 | 1/70 | 0/72 | 0/1 | 0/135 |
| Hand fractureInjury, poisoning and procedural complications | 0/73 | 0/74 | 1/70 | 0/72 | 0/1 | 0/135 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/73 | 0/74 | 1/70 | 0/72 | 0/1 | 0/135 |
| Varicose veinVascular disorders | 0/73 | 0/74 | 1/70 | 0/72 | 0/1 | 0/135 |
| Pulmonary tuberculosisInfections and infestations | 0/73 | 0/74 | 0/70 | 1/72 | 0/1 | 0/135 |
| Urinary tract infectionInfections and infestations | 0/73 | 0/74 | 0/70 | 1/72 | 0/1 | 0/135 |
| Vestibular neuronitisInfections and infestations | 0/73 | 0/74 | 0/70 | 1/72 | 0/1 | 0/135 |
| Benign connective tissue neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/73 | 0/74 | 0/70 | 1/72 | 0/1 | 0/135 |
| Event | Placebo | Ixekizumab 80mg Q4W | Placebo/Ixekizumab 80mg Q4W - Extended Treatment Period | Ixekizumab 80mg Q4W/Ixekizumab 80mg Q4W - Extended Treatment Period | Placebo - Follow-up Period | Ixekizumab 80mg Q4W - Follow-up Period |
|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 2/73 | 5/74 | 20/70 | 25/72 | 0/1 | 0/135 |
| Upper respiratory tract infectionInfections and infestations | 11/73 | 9/74 | 19/70 | 16/72 | 0/1 | 5/135 |
| Vaginal infectionInfections and infestations | 0/8 | 0/10 | 1/8 | 0/10 | 0/1 | 0/16 |
| Pelvic fluid collectionReproductive system and breast disorders | 0/8 | 0/10 | 1/8 | 0/10 | 0/1 | 0/16 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/73 | 6/74 | 7/70 | 4/72 | 0/1 | 4/135 |
| Hepatic function abnormalHepatobiliary disorders | 2/73 | 4/74 | 6/70 | 2/72 | 0/1 | 0/135 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/73 | 2/74 | 4/70 | 6/72 | 0/1 | 0/135 |
| LeukopeniaBlood and lymphatic system disorders | 0/73 | 6/74 | 3/70 | 2/72 | 0/1 | 0/135 |
| Weight increasedInvestigations | 1/73 | 1/74 | 5/70 | 3/72 | 0/1 | 1/135 |
| Alanine aminotransferase increasedInvestigations | 2/73 | 5/74 | 1/70 | 1/72 | 0/1 | 0/135 |
All randomized participants
| Age, Continuous(years) | Placebo | Ixekizumab 80mg Q4W | Total |
|---|---|---|---|
| Mean | 34.4 ± 8.98 | 33.5 ± 8.89 | 33.9 ± 8.92 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab 80mg Q4W | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 65 | 64 | 129 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ixekizumab 80mg Q4W | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 73 | 74 | 147 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab 80mg Q4W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 73 | 74 | 147 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab 80mg Q4W | Total |
|---|---|---|---|
| China | 73 | 74 | 147 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2020 to primary completion in Mar 2021, 11 months.
Results were first posted in Jun 2022, 1 year 2 months after primary completion. A results delay was requested in Mar 2022.
Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab